Novartis has opted out of a collaboration with Mesoblast to develop its stem cell-based therapy remestemcel-L as a treatment for COVID-19, prompting a slump in the biotech's share price.&nb
The UK government has said it will step up its COVID-19 booster vaccination dramatically, with everyone in England aged over 18 offered a third dose before the end of the month.
AstraZeneca's antibody cocktail for COVID-19, now called Evusheld, has become the first drug in the class to be authorised for prevention of infection by the US FDA.
Preliminary study results from South Africa have suggested that antibodies stimulated by Pfizer and BioNTech's Comirnaty are less effective against the new COVID-19 variant Omicron.
The European Commission has moved swiftly to grant full approval to Roche's Actemra/RoActemra as a treatment for severe COVID-19, clearing the drug within 24 hours of a recommendation from
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.